Carbiotix reports promising results from CarbiAXOS metformin study
Carbiotix (publ) ("Carbiotix" or the "Company") announces today promising preliminary results from the 4-month randomised controlled CarbiAXOS intervention study involving type-2 diabetes patients on metformin. The preliminary results reveal that 20% of patients in the intervention cohort responded positively to a prebiotic containing CarbiAXOS, experiencing an average improvement of 15% in HbA1c (blood glucose) levels and an upregulation of Short Chain Fatty Acid (SCFA) levels. These results are in line with our ambition, which was to replicate and substantiate the results from the 2018/2019